Fungaemia due to rare yeasts in a tertiary care university centre within 18 years

Fungaemia due to rare yeasts has been recognised as an emerging, clinically relevant, but less investigated condition. Intrinsic resistance or reduced susceptibility of these species to echinocandins or fluconazole remains as a challenge in empirical treatment.

[1]  L. N. Botello,et al.  Disseminated fungemia by Saprochaete clavata , 2019, Enfermedades infecciosas y microbiologia clinica (English ed.).

[2]  Yee-Chun Chen,et al.  The epidemiology of non‐Candida yeast isolated from blood: The Asia Surveillance Study , 2018, Mycoses.

[3]  B. O. Martínez,et al.  Disseminated fungemia by Saprochaete clavata. , 2018, Enfermedades infecciosas y microbiologia clinica.

[4]  S. Sudhaharan,et al.  Isolation of the Rare Opportunistic Yeast Saprochaete capitata from Clinical Samples-Experience from a Tertiary Care Hospital in Southern India and a Brief Review of the Literature. , 2017, Journal of clinical and diagnostic research : JCDR.

[5]  F. Dromer,et al.  Predisposing factors and outcome of uncommon yeast species-related fungaemia based on an exhaustive surveillance programme (2002–14) , 2017, The Journal of antimicrobial chemotherapy.

[6]  Anupam Pande,et al.  Pseudozyma and other non‐Candida opportunistic yeast bloodstream infections in a large stem cell transplant center , 2017, Transplant infectious disease : an official journal of the Transplantation Society.

[7]  D. Seidel,et al.  Invasive infections due to Saprochaete and Geotrichum species: Report of 23 cases from the FungiScope Registry , 2017, Mycoses.

[8]  J. Guinea,et al.  Fungemia due to rare opportunistic yeasts: data from a population‐based surveillance in Spain , 2017, Medical mycology.

[9]  J. Sobel,et al.  Executive Summary: Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  J. Sobel,et al.  Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  M. Çetin,et al.  Saprochaete capitata as an emerging fungus among patients with haematological malignencies , 2015, Mycoses.

[12]  F. Jardin,et al.  Multicenter Outbreak of Infections by Saprochaete clavata, an Unrecognized Opportunistic Fungal Pathogen , 2014, mBio.

[13]  J. Meis,et al.  ESCMID and ECMM joint clinical guidelines for the diagnosis and management of rare invasive yeast infections. , 2014, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[14]  J. C. García-Ruiz,et al.  Invasive infections caused by Saprochaete capitata in patients with haematological malignancies: report of five cases and review of the antifungal therapy. , 2013, Revista iberoamericana de micologia.

[15]  S. Ichiyama,et al.  Clinical characteristics and risk factors of non-Candida fungaemia , 2013, BMC Infectious Diseases.

[16]  Jun Kato,et al.  Fungemia due to Rhodotorula mucilaginosa after allogeneic hematopoietic stem cell transplantation , 2012, Transplant infectious disease : an official journal of the Transplantation Society.

[17]  L. Pagano,et al.  Uncommon yeast infections in hematological patients: from diagnosis to treatment , 2011, Expert review of anti-infective therapy.

[18]  C. Burgaleta,et al.  Rhodotorula mucilaginosa catheter‐related fungaemia in a patient with multiple myeloma , 2011, Mycoses.

[19]  J. Verhaegen,et al.  Breakthrough Saprochaete capitata infections in patients receiving echinocandins: case report and review of the literature. , 2011, Medical mycology.

[20]  Samuel A. Lee,et al.  Emerging opportunistic yeast infections. , 2011, The Lancet. Infectious diseases.

[21]  D. Kontoyiannis.  Echinocandin-based initial therapy in fungemic patients with cancer: a focus on recent guidelines of the infectious diseases society of america. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  J. Sobel,et al.  Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  D. Horn,et al.  Candidemia in the 21st century. , 2008, Future microbiology.

[24]  M. Pfaller,et al.  Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem , 2007, Clinical Microbiology Reviews.

[25]  L. Pagano,et al.  Invasive Infections Caused by Trichosporon Species and Geotrichum capitatum in Patients with Hematological Malignancies: a Retrospective Multicenter Study from Italy and Review of the Literature , 2005, Journal of Clinical Microbiology.

[26]  M. Pfaller,et al.  Rare and Emerging Opportunistic Fungal Pathogens: Concern for Resistance beyond Candida albicans and Aspergillus fumigatus , 2004, Journal of Clinical Microbiology.

[27]  J. Sierra,et al.  Blastoschizomyces capitatus infection in patients with leukemia: report of 26 cases. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[28]  K. Sepkowitz,et al.  Breakthrough trichosporonosis in a bone marrow transplant recipient receiving caspofungin acetate. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[29]  K. Ackermann,et al.  Medically Important Fungi A Guide To Identification , 2016 .

[30]  Russell E. Lewis,et al.  Rare opportunistic (non-Candida, non-Cryptococcus) yeast bloodstream infections in patients with cancer. , 2012, The Journal of infection.

[31]  Clinical,et al.  Reference method for broth dilution antifungal susceptibility testing of yeasts : Approved standard , 2008 .

[32]  G. Samonis,et al.  Rhodotorula species fungemia: a threat to the immunocompromised host. , 2003, Clinical laboratory.

[33]  D. Larone.  Medically Important Fungi: A Guide to Identification , 1976 .

[34]  K. Sepkowitz,et al.  Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer , 2002 .